Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRINCE: Sotigalimab and/or Nivolumab in Pancreatic Cancer
NCT03214250Phase 2Completed
- Sponsor
- Parker Institute for Cancer Immunotherapy
- Start
- Jul 2017
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sotigalimab in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Parker Institute for Cancer Immunotherapy. Primary endpoints: Phase 1b Primary Safety Outcome and 1-year Overall Survival Rate. Started Jul 2017; status: completed.
02
Drugs
sotigalimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03214250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03214250.